Printer Friendly

CAMBRIDGE NEUROSCIENCE, INC. APPOINTS EDWARD S. CAMPANARO CLINICAL TRIALS MANAGER

 CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) today announced the appointment of Edward S. Campanaro to the newly created position of clinical trials manager. Campanaro has nearly 10 years of clinical research and medical supervisory experience, serving most recently as the Eastern U.S. manager for Medical & Technical Research Associates, Inc., one of the nation's largest independent clinical trials monitoring companies.
 "This year Cambridge NeuroScience has focused on building a strong in-house clinical development capability. With the inception of human clinical trials for Cerestat(TM) at more than 10 sites in New England, Texas and the United Kingdom, we clearly need an effective clinical development team," said Elkan Gamzu, Ph.D., president and chief operating officer. "We believe Ed's expertise will prove to be an important component of success."
 As regional manager for Medical & Technical Research Associates in Wellesley, Mass., Campanaro supervised a staff of research associates that was responsible for monitoring and evaluating clinical research programs for major U.S. and international pharmaceutical firms. He was promoted to manager from clinical research associate in 1990. Previously, Campanaro served as a nursing supervisor at the Massachusetts General Hospital and the United States Air Force.
 Campanaro received a medal of commendation from the U.S. Air Force in 1986, prior to receiving an honorable discharge. He received a Bachelor of Science degree from the University of Massachusetts, and his Massachusetts Nursing License in 1982. He is a nationally accredited critical care nurse (CCRN), and a member of the Associates of Clinical Pharmacology.
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceuticals with a focus on nerve cell survival. The company is developing a number of products to treat stroke, traumatic brain injury, schizophrenia and chronic neurodegenerative disorders such as diabetic peripheral neuropathy and multiple sclerosis.
 -0- 8/10/93
 /CONTACT: Philip V. Holberton, vice president and CFO, Cambridge NeuroScience, Inc., 617-225-0600, ext. 106; Christopher Taylor, account executive of Feinstein Partners Inc., 617-577-8110, for Cambridge NeuroScience/
 (CNSI)


CO: Cambridge NeuroScience ST: Massachusetts IN: MTC SU: PER

DJ-CM -- NE001 -- 1525 08/11/93 09:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 1993
Words:353
Previous Article:OLYMPIC FINANCIAL LTD. OPENS ORLANDO OFFICE
Next Article:TYCO ANNOUNCES 1993 EARNINGS OF $2.31, BEFORE RESTRUCTURING CHARGES AND ACCOUNTING CHANGES
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters